The Alzheimer's Disease Centers Program: updates

Nina Silverberg, Ph.D

Director, Alzheimer's Disease Centers Program, NIA

Presented at Directors Meeting, October 20, 2018, Atlanta, GA

Polleverywhere Feedback

Using the Poll Everywhere app on your smartphone:

- 1. Search for "Poll Everywhere" in your phone's app store and download it (it's free).
- 2. Launch the app.
- 3. Join the presentation: uwnacc240 (PollEv.com/uwnacc240).
- 4. Look for the active survey presentation.
- 5/ Press Start Survey and begin your instant feedback on the screen.

Using your phone by texting (without downloading app):

- 1. Text UWNACC240 to 22333 to join survey
- 2. You will receive a reply "You've joined UW NACC's session (UWNACC240)
- 3. Your phone number is private.
- 4. Text your answers during the active survey question. Listen to the presenter.

ADC Meeting Structure

- May 2019
 - Date change to Thursday/Friday, May 2 and 3
- Spring Meetings
 - AAN requests that we shift to Thursday/Friday if they're helping us book discounted space. We can accept or book our own space keeping Friday/Saturday
- Virtual Site Visits
 - Volunteers have not been forthcoming
 - May 2019 Biomarkers
 - Oct 2019 REC Junior Faculty Poster Session

Applications

- No more P50 revision applications; focus on your new application
 - ►NOT-AG-18-031
- Submit Final RPPR when you are a P50 transitioning to the new FOA in your final year.
- We don't know when the new FOA will be out.

Rec Table 1 – from ADC Progress Report Instruction

Table 1 Summary Table of REC Trainees – Year XX							
Last, First Name	Level of Training	Area of Research	Progress				
Adams, P.	Post-Doctoral	Episodic memory on decision making	Co-authored paper, poster presentation, experience in a number of labs				

Modified Rec Table 1

Table 1		Summary Table of REC Trainees – Year XX					
RPPR year	Last, First Name	Level of Training	Area of Research	Progress track			
2017	Adams, P.	Post-doctoral	Episodic memory on decision making	# of co-authored papers, # posters, training award, experience in multiple labs			
2018							
2019							
2020							
2021							

Summary of REC trainees (2018)

ADCs (10)	REC Trainees	Junior faculty	Postdoc Residents		Under- graduates	Publications Grants
Range	5-60	3-12	1-15	6-26	4-18	3-20
Total	263	28	74	110	52	105

Mark your calendar for upcoming REC activities

Workshop for REC postdocs

- ► March 13, 2019
- Grant writing workshop
- 30 post-doctoral trainees
- ► Conjunction with ADRD summit March 14-15, 2019
- Bethesda, MD

REC Junior faculty

- Oct 11, 2019
- Presentation (5 min)
- Poster Sessions
- 30 Junior faculty
- Conjunction with Fall ADC meeting, Oct 11-12, 2019
- ► St. Louis, MO

Staff Updates

Dr. Cerise Elliott is now officially:

Co-Director of the ADC Program!

Dr. Yuan Luo will be guiding the RECs

NEUROPATHOLOGY STEERING CMTE

- NeurobioBank
- Tissue and Biospecimen Resource Locator NACC
- Transmissibility meeting
- **■** TDP43 Meeting
- DS Autopsy

Current Steering Committees

- Élected Representation
 - ADC Executive Committee July
 - NACC Steering Committee July
 - Administrators Steering Committee August/September
 - Clinical Core Steering Committee January
 - Neuropathology Core Steering Committee July
 - ORE Core Steering Committee July
 - Data Core Steering Committee July

Biomarker Steering Committee? REC Steering Committee?

Interest Groups

- 2017 Listservs created
 - Disclosure Work Group
 - ► African American Recruitment
 - **■**Latino
 - Imaging
 - **■** Biomarkers

UDS Workgroup update

- Survey completed
- Results compiled: looks like very few whole forms would be eliminated. One that stuck out was biomarkers
- Met with group to review with Bud pointed out that many are already optional
- Next steps:
 - Other ways to evaluate utility/effectiveness
 - ■Should any additional items be made optional
 - Are there gaps? Are we at the cutting edge, leading the field?
 - Control visits annual?

FY2018 NACC Augmentations

- Imaging
- Digital Biomarkers
- CSF study
- Down Syndrome
- FTD and DLB modules
- Affiliated Studies

Attention, ADCs

Promote your studies and **share** them with researchers around the world

Does your Center have a study that may be a resource for researchers outside your ADC? If so, NIA invites you to promote it on the NACC website.

Just fill out a quick questionnaire, and NACC will post a brief description, along with your logo and a link to the study website.

GET THE QUESTIONNAIRE: naccmail@uw.edu

Down Syndrome

- ABC-DS Alzheimer's Biomarkers Consortium — Down Syndrome https://www.nia.nih.gov/research/abc-ds
- https://www.nih.gov/include-project

- Autopsy
- DS module
- DS Work Group




Exploring the Connection Between Down Syndrome and Alzheimer's Disease

The ABC-DS study is a joint study conducted by two groups of research collaborators -Neurodegeneration in Aging Down Syndrome (NiAD) and Alzheimer's Disease in Down Syndrome (ADDS)—and is currently funded at \$43 million by the National Institute on Aging (NIA) and the Eunice Kennedy Shriver National Institute of Child

The INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) project was launched in June 2018 in support of a Congressional directive in the fiscal year (FY) 2018 Omnibus Appropriations. The directive calls for a new trans-NIH research initiative on critical health and quality-oflife needs for individuals with Down syndrome. NIH is dedicating \$22.2 million for INCLUDE research, bolstering total funding for Down syndrome research in FY2018 to an estimated \$59 million, with further support anticipated in FY2019 and beyond, pending availability of funds.

INCLUDE will investigate conditions that affect individuals with Down syndrome and the general population, such as Alzheimer's disease/dementia, autism, cataracts,

INCLUDE Project Research Plan



Thinkstock

Research Centers Collaborative Network (RCCN)



- Goal: Catalyzing cross-disciplinary research across the NIA Center Programs
- Webinar Series
- Workshop: Achieving and Sustaining Behavior Change in Older Adults, December 6-7th, 2018 in Bethesda, MD.10 travel awards
- RFA for Pilot Awards to foster inter-center program collaborations will be issued in **December** on "Achieving and Sustaining Behavior Change in Older Adults."
- Workshop: May/June 2019 on Sex/gender differences in aging
- <u>www.rccn-aging.org</u> @rccnaging




EMORY

SageBionetworks

Dorothy Farrar-Edwards
Hannah Blazel
Erin Chin
Nichelle Cobb
Ken Croes


Jim Lah Cecelia Manzanares Felicia Golstein



Christine Suver
Woody McDuffy
Stockard Simon
Amy Tran
Jennifer Hamann
Meg Doerr
John Wilbanks
Lara Mangravite


ADRC Study coordinators Volunteers

eConsent Narrative Self-guided exploration



NIA GLOBAL UNIQUE IDENTIFIER (GUID) PORTAL

Progress to Date & Next Steps



- Live NIA GUID portal launched July 1 and rolled out to ADCs on July 17;
- Portal allows users to:
 - create actual and pseudo GUIDS;
 - Upload batch information to generate multiple
 GUIDS
- Account access and set-up is managed by NIA BRICS Operations Team
 - 25 Users
 - 52 GUID entries

https://bricsguid.nia.nih.gov/portal/guid/guidAction!landing.action







Welcome Administrator, Erika | Log Out

Workspace

Account Management

GUID (Global Unique Identifier)

GUID Tool GUID Overview

Create GUIDs My GUIDs

GUID Admin

GUID Overview


The GUID Tool is a customized software application that generates a Global Unique Identifier for each study participant. A GUID is a subject ID that allows researchers to share data specific to a study participant. without exposing personally identifiable information (PII). A GUID is made up of random alpha-numeric characters and is NOT generated from PII/PHI. By using GUIDs in your research data, the system can associate a single research participant's genetic, imaging, clinical assessment data even if the data was collected at different locations or through different studies.

In order to submit data to the system, the system expects all prospective studies to include a GUID in the data submission. For retrospective studies, the team understands that the participant data needed to generate a GUID may not be available. To account for this, the capability to generate pseudo-GUIDs is provided. However submitting data with pseudo-GUIDs, silos the associated research data from the other data associated with valid GUIDs.

Fields required to generate a GUID

In order to generate a GUID, the following PII is required:

- · Complete legal given (first)name of subject at birth
- If the subject has a middle name
- . Complete legal family (last) name of subject at birth
- Day of birth
- · Month of birth
- Year of birth
- Name of city/municipality in which subject was born
- · Country of birth



If you do not have all of the required information, you can create a pseudo GUID

Biomedical Research Informatics Computing System (BRICS)

National Institutes of Health (NIH) National Institute of Aging (NIA) Website: https://www.nia.nih.gov @

NIH ... Turning Discovery Into Health





Next Steps

LAUNCH NIA GUID PORTAL (July 2018)

Initial Launch to ADCs



Provide continuous user feedback to developers

CENTRALIZED NIA/NINDS PORTAL (December 2018)

Synchronize records of participants in NIA- and NINDS-funded clinical studies



ADOPTION OF PORTAL ACROSS NIA CLINICAL
SITES (October 2019)
Roll out portal to all NIA Sites

Office of Research and Development Three Strategic Priorities



Access to High Quality
Clinical Trials
Increase Veterans' access to
clinical trials.

Greater choice for Veterans.

Modernizing our system.

Focus resources more efficiently.

Access.

Lead: Grant Huang, MPH, PhD



Substantial Real-World Impact Increase the real-world impact of VA research.

Modernizing our system.

Focus resources more efficiently.

Lead: Amy Kilbourne, PhD, MPH



VA Data as a National Resource
Increase the good that
VA Data can do.

Modernizing our system.

Focus resources more efficiently.

Lead: Scott Duvall, PhD







Background

- Clinical trials are a key part of the national healthcare and research landscape.
- Trial sponsors include federal, non-profit and industry sources.
 - Industry trials have grown at the largest rate (17%) since 2006 (Ehrhardt, et al. JAMA, 2015)
- Clinical trials offer several opportunities:
 - Patient access to cutting edge therapies
 - Clinician access to research and collaborative activities
 - Mutually beneficial partnerships
- VA has strong clinical trials capabilities and resources
 - Much are internally focused and directed





Access to Clinical Trials Initiative

Goals:

- Establish an organized national capability for VA to partner in high quality clinical trials
 - Efficient processes and capabilities for initiating clinical trials in VA health care system
 - Models for partnerships
- Provide more Veterans and investigators to opportunities to participate in industry and federally sponsored clinical trials on novel therapies
- Long-term: To advance VA's role in the national clinical trials enterprise





Access to Clinical Trials (ACT) for Veterans

- Since April 2018 Summit, monthly updates continue to be provided to stakeholders (<u>clinicaltrials@navref.org</u>)
- 5 work groups established to address priorities for initiating trials:
 - Single point of contact model
 - Establishing set of key VA capabilities, assets and processes for industry partners interested in initiating opportunities
 - Establishing set of requirements VA needs to fully consider opportunities
 - Creating and maintaining a process map for start-up activities
 - Developing VA Central IRB capabilities to accommodate industry-sponsored trials





NCI And VA Interagency Group to Accelerate Trials Enrollment (NAVIGATE)

- 12 sites selected for infrastructure support and to provide leadership for national network for NCI funded trials
 - 1 VA/CSP supported coordinating center

Collaboration between NCI and the VA to facilitate enrollment of Veterans into NCI funded clinical trials.

- Opportunity for government agencies to partner at the national level to make clinical trials more accessible, and
- Accelerate cancer research by testing new cancer therapies to lessen the burden of cancer and its symptoms, as well as novel approaches to the prevention and early detection of cancer



